Antibody light chains dictate the specificity of contact hypersensitivity effector cell suppression mediated by exosomes by Nazimek, Katarzyna et al.
 International Journal of 
Molecular Sciences
Article
Antibody Light Chains Dictate the Specificity of
Contact Hypersensitivity Effector Cell Suppression
Mediated by Exosomes
Katarzyna Nazimek 1,2 , Philip W. Askenase 2 and Krzysztof Bryniarski 1,2,*
1 Department of Immunology, Jagiellonian University Medical College, 31-121 Krakow, Poland;
katarzyna.nazimek@uj.edu.pl
2 Section of Rheumatology, Allergy and Clinical Immunology, Yale University School of Medicine,
New Haven, CT 06520, USA; philip.askenase@yale.edu
* Correspondence: mmbrynia@cyf-kr.edu.pl; Tel.: +48-12-632-58-65
Received: 2 August 2018; Accepted: 30 August 2018; Published: 7 September 2018


Abstract: Antibody light chains (LCs), formerly considered a waste product of immunoglobulin
synthesis, are currently recognized as important players in the activation of the immune
response. However, very little is known about the possible immune regulatory functions of LCs.
Recently, we reported that hapten-specific LCs coat miRNA-150-carrying exosomes produced
by CD8+ suppressor T cells downregulating the contact hypersensitivity (CHS) reaction in an
antigen-specific manner, in mice tolerized by intravenous administration of a high dose of
hapten-coupled syngeneic erythrocytes. Thus, the current studies aimed at investigating the role
of hapten-specific LCs in antigen-specific, exosome-mediated suppression of CHS effector cells.
Suppressor T cell-derived exosomes from tolerized B-cell-deficient µMT−/−, NKT-cell-deficient
Jα18−/−, and immunoglobulin-deficient JH−/− mice were nonsuppressive, unless supplemented
with LCs of specificity strictly respective to the hapten used for sensitization and CHS elicitation
in mice. Thus, these observations demonstrate that B1-cell-derived LCs, coating exosomes
in vivo and in vitro, actually ensure the specificity of CHS suppression. Our research findings
substantially expand current understanding of the newly discovered, suppressor T cell-dependent
tolerance mechanism by uncovering the function of antigen-specific LCs in exosome-mediated,
cell–cell communication. This express great translational potential in designing nanocarriers for
specific targeting of desired cells.
Keywords: antibody light chains; cell–cell signaling; immune regulation; immune suppression;
exosomes; extracellular vesicles; miRNA
1. Introduction
Freely circulating antibody light chains (LCs) were formerly considered a waste product of
immunoglobulin synthesis by B lymphocytes. However, currently the biological functions of LCs
are being recognized. Due to their involvement in pathogenesis of various diseases, LCs are now
considered as possible diagnostic markers [1–3]. Further, LCs play an important role in activation of
mast cells and neutrophils, as well as in humoral immunity by supporting the antigen binding with
sufficient affinity by specific antibodies [1]. This is often associated with the development of various
chronic inflammatory disorders and tumor-related inflammation, in which LCs seem to promote the
pathological immune reactivity of particular cells [1,4,5]. On the other hand, very little is known about
the possible beneficial immune regulatory function of antibody LCs.
In contrast to B2 population, B1 lymphocytes are activated in a T cell-independent manner,
by hapten-self-protein complexes and IL-4 released by hepatic natural killer T (NKT) cells stimulated
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with endogenous glycolipids [6–11]. During the humoral immune response B2 lymphocytes generate
highly antigen-specific antibodies of various classes, depending on the route of administration
of T-dependent antigen and its character. Whereas, B1 lymphocytes mostly produce natural IgM
antibodies characterized by low specificity to T-independent antigen due to the lack of signals from
helper T cells that could promote B cell maturation, immunoglobulin class switching, and generation
of memory cells [6]. However, B1 lymphocytes are involved in an early phase of elicitation of contact
hypersensitivity (CHS) reaction by delivering IgM antibodies and their LCs that bind haptenized
antigens to further activate complement. This results in activation of local inflammation, predominantly
mediated by mast cells and neutrophils, which finally allows for migration and recruitment of
antigen-specific effector T cells to the site of hapten deposition to elicit the local symptoms of CHS
reaction [6–11]. Interestingly, activation of innate-like B cells, likely resembling B1 lymphocytes,
but expressing regulatory phenotype, by mouse invariant NKT cells was recently reported [12].
This suggests that B1 cells may also play a role in immune regulation. Furthermore, one of the B1a
cell subsets was shown to produce IgM antibodies and LCs that express high affinity to antigen due
to immunoglobulin V-region mutations caused by activation-induced cytidine deaminase (AID) [6].
These B1a cells occurred to mediate an early, protective immune response to pneumococci in a mouse
model of pneumococcal pneumonia [13].
Formerly, it was reported that intravenous administration of a high dose of syngeneic mouse red
blood cells (MRBCs) coupled with hapten prior to contact sensitization with the same hapten leads to
the suppression of CHS reaction in mice [14]. Then, it occurred that the delivery of haptenized MRBCs
induces CD8+ suppressor T (Ts) lymphocytes responsible for downregulation of CHS reaction [14,15].
Recently, we have shown that Ts cells, when activated by intravenous administration of a high
dose of syngeneic MRBCs coupled with hapten, release miRNA-150-carrying exosomes that actually
suppress CHS reaction induced with the same hapten [16–18]. After detailed characterization of Ts cell
exosomes [16] (Figure S1), by employing miRNA sequencing, antimiRs and finally miRNA-150−/−
mice, we proved that miRNA-150 is a crucial regulatory molecule derived by the exosomes [16]
to antigen-presenting cells finally suppressing CHS effector T lymphocytes [18]. Experiments with
non-cross-reacting haptens; i.e., trinitrophenol (TNP) and oxazolone (OX), proved that Ts cell-derived
exosomes suppress CHS reaction in an antigen-specific manner [16,17]. This surprising observation
further led to the discovery that Ts cell-derived exosomes are coated with antibody LCs, as
demonstrated by the means of flow cytometry (Figure S1 and Figure 5B of a past paper [16]).
Afterwards, the experiments with pan immunoglobulin JH−/− mice demonstrated that the surface
coating of Ts cell-derived exosomes with hapten-specific LCs is essential for ensuring their suppressive
activity in CHS [16]. Conversely, JH−/− mouse Ts cell exosomes in vitro inhibited the IL-2-dependent
viability of HT-2 T cells in a miRNA-150-dependent manner, which confirmed that they carry
miRNA-150 and are only lacking LCs on their surface [16]. Additionally, coating with hapten-specific
LCs enabled exosome separation by antigen affinity chromatography [16] and was suspected to
provide the ability of Ts cell exosomes to target hapten-primed antigen-presenting cells that ultimately
inhibit CHS effector T cells [18,19]. Therefore, we assumed that LCs in fact could be responsible for
antigen-specificity of CHS suppression mediated by Ts cell-derived exosomes, however it remained
a matter of speculation. Since defining the beneficial immune regulatory function of free LCs would
not only allow us to fully understand the exosome-mediated cellular interactions and would also
favor the recognition of the biological importance of LC, we therefore have undertaken the current
studies to investigate the role of hapten-specific LCs in an antigen-specific, Ts cell-exosome-mediated
suppression of CHS effector cells.
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2. Results
2.1. B Cells Deliver Hapten-Specific LCs for Coating of Ts Cell-Derived Exosomes to Enable Their Suppressive Function
We have previously observed that coating of Ts cell-derived exosomes with hapten-specific LCs is
required to accomplish exosome suppressive function [16]. However, it was not clear if administration
of haptenized MRBCs activates B lymphocytes along with Ts cells, and whether they are necessary
for generation of regulatory exosomes by Ts cells. To test these assumptions, we have administered
syngeneic MRBCs coupled with OX hapten into wild type (WT) and B cell-deficient µMT mice prior
to their contact sensitization with OX and elicitation of CHS ear swelling response. While injection
of haptenized sMRBC to WT mice led to significant suppression of CHS, it failed to inhibit the CHS
reaction in B cell-deficient mice (Figure 1a, group D vs. C and B vs. A). This implied that the suppression
of CHS cannot be developed in the absence of B cells. To examine if B cells play a role already at the
time of exosome generation or, instead, they enable exosomes to accomplish their function, we have
collected lymph nodes and spleens of hapten-coupled-MRBC-tolerized µMT mice and processed their
single-cell-suspensions for Ts cell exosome isolation [16–18]. The yielding µMT mouse exosomes
were then used to treat adoptively transferred CHS effector cells, but they failed to suppress elicited
CHS reaction (Figure 1b, group C vs. A and B). Remarkably, supplementation of µMT mouse Ts
cell exosomes with OX-specific LCs restored their suppressive activity (Figure 1b, group D vs. A),
while addition of these LCs to initially nonsuppressive, control nanovesicles [16–18] had no inhibitory
effect (Figure 1b, groups E and F vs. A). These observations allowed us to conclude that B cells are not
necessary for generation of suppressive exosomes by Ts cells, but, instead, they deliver hapten-specific
LCs for coating of exosomes, which is crucial to accomplish their function. Further, as LCs alone,
or when coating the nonsuppressive nanovesicles, were noninhibitory, we considered that they solely
enable execution of suppression by Ts cell exosomes.
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Figure 1. Effects of intravenous administration of a high dose of oxazolone (OX)-coupled syngeneic 
mouse red blood cells (MRBC) to wild type (C57BL/6) or B cell-deficient µMT mice on contact 
hypersensitivity (CHS) reaction. CHS reaction was measured as ear swelling response either (a) in 
actively sensitized mice that had been administered with OX-MRBC or (b) in recipients of CHS 
effector cells incubated with exosomes (in some instances supplemented with anti-OX antibody light 
chains—LCs) generated by lymph node and spleen T suppressor cells of mice injected with OX-
MRBC. Bars express delta ± standard error (SE). n = 5 mice in each group. ** p < 0.01; *** p < 0.001. 
2.2. CHS Reaction Is Not Suppressed in the Absence of NKT Cells 
According to previous findings, NKT cell-activated B1 lymphocytes [6–10] and their derived LCs 
are involved in the development of an early phase of CHS effector response [6,20,21]. Thus, we 
speculated that the B1 cell subpopulation may also be responsible for the delivery of hapten-specific 
LCs then coating suppressive exosomes. We have initially verified this hypothesis by employing Jα18 
mice that lack NKT cells, but have conventional T cells [22], so thus are characterized by impaired 
activation of B1 cells [8]. Tolerization of Jα18 mice with haptenized MRBCs did not cause the 
suppression of CHS reaction (Figure 2a, group D vs. C). However, the generation of Ts cell exosomes 
stimulated by hapten-coupled MRBCs was preserved in Jα18 mice, and the suppressive activity of 
these exosomes was again restored by supplementation with hapten-specific LCs (Figure 2b, group 
D vs. A and C). This implied that, indeed, B1 lymphocytes activated by NKT cells at the time of 
contact sensitization with hapten [6–10] are the source of hapten-specific LCs for coating of Ts cell-
derived exosomes. 
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2.2. CHS Reaction Is Not Suppressed in the Absence of NKT Cells
According to previous findings, NKT cell-activated B1 lymphocytes [6–10] and their derived
LCs are involved in the development of an early phase of CHS effector response [6,20,21].
Thus, we speculated that the B1 cell subpopulation may also be responsible for the delivery of
hapten-specific LCs then coating suppressive exosomes. We have initially verified this hypothesis by
employing Jα18 mice that lack NKT cells, but have conventional T cells [22], so thus are characterized
by impaired activation of B1 cells [8]. Tolerization of Jα18 mice with haptenized MRBCs did not
cause the suppression of CHS reaction (Figure 2a, group D vs. C). However, the generation of Ts cell
exosomes stimulated by hapten-coupled MRBCs was preserved in Jα18 mice, and the suppressive
activity of these exosomes was again restored by supplementation with hapten-specific LCs (Figure 2b,
group D vs. A and C). This implied that, indeed, B1 lymphocytes activated by NKT cells at the time
of contact sensitization with hapten [6–10] are the source of hapten-specific LCs for coating of Ts
cell-derived exosomes.
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MRBC. Bars express delta ± standard error (SE). n = 5 mice in each group. ** p < 0.01. 
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2.3. CHS Reaction Is Suppressed by Exosomes in Mice Tolerized with Syngeneic MRBCs Regardless of Their
Hapten Coupling
According to the current findings, we assumed that B1 cells delivering LCs are activated at
the time of contact sensitization, but not under the influence of intravenously administered MRBCs
coupled with hapten. Then, the suppression of CHS should be accomplished regardless of the hapten
coupling of MRBCs. Thus, we have administered mice with either TNP-MRBCs or OX-MRBCs prior to
contact sensitization with either PCL or OX. In all cases elicited CHS ear swelling was significantly
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inhibited (Figure 3a, groups B and C vs. A, and E and F vs. D). Further, we have collected lymph node
and spleen cells of those mice and processed them as for Ts cell exosome harvesting. Yielded exosomes
were used to treat adoptively transferred TNP-specific or OX-specific CHS effector cells, which led to
significant suppression of elicited CHS reaction (Figure 3b, groups B and C vs. A, and E and F vs. D).
This allowed us to conclude that haptenized MRBC administration induces Ts cells to release exosomes
that gain, after contact sensitization, the surface coating with LCs of specificity dictated by sensitizing
hapten, activating B1 cells.
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 15 
 
node and spleen cells of those mice and processed them as for Ts cell exosome harvesting. Yielded 
exosomes were used to treat adoptively transferred TNP-specific or OX-specific CHS effector cells, 
which led to significant suppression of elicited CHS reaction (Figure 3b, groups B and C vs. A, and E 
and F vs. D). This allowed us to conclude that haptenized MRBC administration induces Ts cells to 
release exosomes that gain, after contact sensitization, the surface coating with LCs of specificity 
dictated by sensitizing hapten, activating B1 cells. 
 
(a) 
 
(b) 
Figure 3. Effects of intravenous administration to CBA mice of a high dose of either trinitrophenol 
(TNP) or oxazolone (OX)-coupled syngeneic mouse red blood cells (MRBC) on contact 
hypersensitivity (CHS) reaction to TNP-chloride (PCL) or OX hapten. CHS reaction was measured as 
ear swelling response either (a) in actively sensitized mice that had been administered with hapten-
coupled MRBC or (b) in recipients of CHS effector cells incubated with exosomes generated by lymph 
node and spleen T suppressor cells of mice either injected with TNP-MRBC and sensitized with PCL, 
injected with OX-MRBC and sensitized with PCL, injected with OX-MRBC and sensitized with OX, 
or injected with TNP-MRBC and sensitized with OX. Bars express delta ± standard error (SE). n = 5 
mice in each group. * p < 0.05; ** p < 0.01; *** p < 0.005. 
Figure 3. Effects of intravenous administr to CBA mice of a high dose of ither initrophenol
(TNP) or oxazol ne (OX)-coupled syngeneic mouse red blood cells (MRBC) on contact hypersensitivity
(CHS) reaction to TNP-chloride (PCL) or OX hapten. CHS reaction was measured as ear swelling
response either (a) in actively sensitized mice that had been administered with hapten-coupled MRBC
or (b) in recipients of CHS effector cells incubated with exosomes generated by lymph node and spleen
T suppressor cells of mice either injected with TNP-MRBC and sensitized with PCL, injected with
OX-MRBC and sensitized with PCL, injected with OX-MRBC and sensitized with OX, or injected with
TNP-MRBC and sensitized with OX. Bars express delta ± standard error (SE). n = 5 mice in each group.
* p < 0.05; ** p < 0.01; *** p < 0.005.
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2.4. CHS Reaction to TNP Hapten Is Suppressed in Mice Administered with Non-Self-Protein-Coupled
Syngeneic MRBCs
Afterwards, we attempted to assess whether the hapten-coupling of syngeneic MRBCs somehow
supports or restricts the subsequent ability of Ts cell exosomes to be coated with hapten-specific
LCs. For this purpose, we have administered mice with either TNP-coupled or bovine serum
albumin (BSA)-coupled MRBCs prior to contact sensitization with PCL, which in both cases led to
significant suppression of elicited CHS reaction (Figure 4, groups B and C vs. A). Thus, we concluded
that administration of altered-self MRBCs is sufficient to induce Ts cells to release suppressive
exosomes that become functionally active when coated with LCs of specificity ultimately dictated by
sensitizing antigen.
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surface. To ultimately confirm this hypothesis, firstly we have isolated Ts cell exosomes from OX-
MRBC-administered JH−/− mice and supplemented them with anti-TNP LCs prior to treatment of 
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2.5. Coating of Exosomes with LCs Ensures the Antigen-Specificity of Suppression of CHS Effector Cells
We have previously shown that pan immunoglobulin-deficient JH−/− mouse Ts cells produce
exosomes that suppress CHS effector cells by delivering miRNA-150, but after coating with
hapten-specific LCs [16]. Herein we have also demonstrated that LC supplementation activates
Ts cell exosomes of B cell-deficient mice for suppression. Nonetheless, it has been unconfirmed
whether only LCs possess such an activity. Thus, we administered JH−/− mice with haptenized
MRBCs to obtain Ts cell exosomes, that we have supplemented with hapten-specific antibody LCs or
heavy chains prior to treatment of adoptively transferred CHS effector cells. Remarkably, only LCs
occurred to be able to restore the suppressive activity of JH−/− mouse Ts cell exosomes that alone
were noninhibitory (Figure 5a, group D vs. A, C and E). The above observations strongly suggested
that the antigen-specificity of Ts cell exosome action is shaped by hapten-specific LCs coating their
surface. To ultimately confirm this hypothesis, firstly we have isolated Ts cell exosomes from
OX-MRBC-administered JH−/− mice and supplemented them with anti-TNP LCs prior to treatment
of TNP-specific CHS effector cells. This led to significant suppression of CHS reaction elicited with
TNP hapten (Figure 5b, group D vs. A). Furthermore, we have isolated Ts cell exosomes from
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TNP-MRBC-administered JH−/− mice and supplemented them with anti-OX LCs prior to treatment
of TNP-specific CHS effector cells, which failed to suppress elicited CHS reaction, while anti-TNP
LC-coated exosomes were strongly suppressive (Figure 5c, group D vs. A and C). Analogously, Ts cell
exosomes of OX-MRBC-administered JH−/− mice, when supplemented with anti-TNP LCs, failed to
inhibit adoptively transferred OX-specific CHS effector cells, while anti-OX LC-coated exosomes were
suppressive (Figure 5c, group H vs. E and G). These findings unequivocally proved that hapten-specific
antibody LCs confer antigen-specificity of Ts cell exosome-mediated suppression of CHS effector cells.
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3. Discussion
Hapten-specific LCs, secreted by B1 cells activated at the time of contact sensitization, are well
recognized agents involved in initiation of the effector phase of CHS reaction [6]. They mostly coat
the membrane of mast cells to then bind the haptenic antigen, which as a consequence induces
mast cell release of proinflammatory and vasoactive mediators and initiates the inflammatory
reaction. This is crucial to enable the migration of CHS effector T cells to the site of hapten
deposition [23]. Further, antigen-specific LC-mediated activation of mast cells is also observed
in various allergic [24] and chronic inflammatory disorders as an alternate pathway to surface
receptor-bound IgE cross-linking [4]. The proinflammatory activity of LCs was recently considered in
pathogenesis of different inflammation-related diseases, like inflammatory bowel disease [25], as well
as lung [26] and renal disorders [25]. LCs were found in urinary exosome-like nanovesicles collected
from patients with light chain amyloidosis [27]. Freely circulating LCs are also suspected to induce
tissue injury in multiple myeloma patients and they could be contained in serum extracellular vesicles
to support their docking to endothelial and myocardial cells [28]. On the other hand, very little is
known about the possible beneficial immune regulatory role of antigen-specific LCs. Our current
research findings demonstrated that hapten-specific LCs confer the antigen specificity of immune
tolerance mechanism mediated by miRNA-150-carrying exosomes. To our best knowledge, this is
the first demonstration of the role of LCs in cell-to-cell communication via exosomes, which ensures
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the specificity and selectivity of cell targeting by exosome carriers. This in turn provides the highly
specific pathway of delivery of exosome cargo to the desired acceptor cell [19,29].
Our results (Figure 6) showed that hapten-specific LCs coating Ts cell-derived exosomes are
secreted by B1 cells, activated by NKT cells at the time of skin sensitization with hapten [6–11].
Hence, B1 cells are involved not only in activation [20], but likely also in regulation of CHS
reaction. Further, our results provided the first demonstration of the downregulatory function of
hapten-specific LCs during the course of CHS reaction, executed by complementing suppressive
exosomes with antigen-recognition system. It is worth noting that multiple adjacent LCs coated on
the exosome surface likely gain great avidity, enabling the strictly specific binding of the antigen [19].
Consequently, this would allow exosomes to target those antigen-presenting cells that express the
corresponding antigenic determinant complexed with MHC, as is suspected in the case of Ts cell
exosomes [18,19]. Recently exosomes are considered a promising natural nanocarriers of genetically
encoded information and biologically active compounds for various therapeutic applications [19,29].
Thus, such a strict specificity of antigen binding by LC-coated exosome carriers, addressing them to
selected cells, has great clinical implications.
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of transplanted organs. On the other hand, however, this mechanism might also be involved in the
unwanted immune tolerance that may develop during chronic infections.
The process of coating Ts cell exosomes by hapten-specific LCs remains uncharacterized and
requires further studies. However, our preliminary results suggest the involvement of exosome
membrane phospholipids [19]. Along these lines, saturated phosphocholine lipids in monocyte
membranes were shown to bind LCs that were suggested to support the process of antigen capturing
and engulfment [30]. In addition, LC aggregates coupled to phospholipids were found on myeloma
plasma cells [31].
Extracellular vesicles, exosomes especially, are considered very promising therapeutic delivery
tools and biomarkers of various diseases [29,32–36]. Accordingly, liposomes coated with monoclonal
antibodies were designed for clinical application to specifically deliver therapeutic agents [37].
Data reported here and previously [16,17] defined a similar mechanism involving exosomes and
LCs that occurs physiologically during the process of immune response regulation. In addition,
lipids, supposedly, are also binding sites for LCs onto exosome membrane. It is worth noting that
physiologically, in vivo produced exosomes express much greater potential as natural therapeutic
agents and nanocarriers than synthetically engineered liposomes [38]. Thus, liposomes seem not to be
able to fully substitute exosomes.
Among other extracellular vesicles, exosomes were found to carry various bioactive compounds,
including nucleic acids, proteins, and lipids that may be immunogenic or express immune regulatory
properties [39], thus, constituting cell–cell communication conveyors of great interest and numerous
potential applications [40]. To deliver their cargo, exosomes in most cases fuse with targeted cells [41].
However, intensive studies have been undertaken to assess whether exosomes target the eventual
acceptor cell selectively and specifically. Our current results bring novel important discovery in
this regard by demonstrating that exosomes could be surface coated with hapten-specific LCs,
which allows to execute the exosome function in an antigen-specific manner by targeting particular
cell population. Thus, specific LCs that coat exosomes dictate the specificity of cell targeting.
Accordingly, the manipulable specificity of cell targeting by exosomes would allow for the delivery of
selected cargo to desired acceptor cells, and specific LCs seem to be promising candidates to ensure
such a possibility for further therapeutic utilization.
To summarize, current research expands our understanding of the newly discovered tolerance
mechanism mediated by Ts cell exosomes carrying miRNA-150 [15–19] by uncovering the function of
antigen-specific LCs in exosome-mediated cell–cell communication that express great translational
potential in designing nanocarriers for specific targeting of desired cells.
4. Materials and Methods
4.1. Mice
Eight to 12-week old mice of the following inbred strains: BALB/c, C57BL/6, pan
immunoglobulin-deficient JH−/− (BALB/c background) [16], and B cell-deficient µMT mice (C57BL/6
background) [20] or NKT cell-deficient Jα18−/− mice (C57BL/6 background) [22] were from Jackson
Laboratories (Bar Harbor, ME, USA) and CBA mice were from the Breeding Unit of the Jagiellonian
University Medical College, Faculty of Medicine (Krakow, Poland). Mice were kept in standard
conditions and fed autoclaved food and water ad libitum.
4.2. Ethics Statement
This study was carried out in accordance with the principles of the Basel Declaration.
All experiments were approved by the Institutional Animal Care and Use Committee of the Yale
University, New Haven, CT, USA (Permit Number 07381) and First Local Ethics Committee of the
Jagiellonian University, Krakow, Poland (Permit Number 40/2011 and 106/2012). All procedures were
performed under ether or isoflurane anesthesia, and all efforts were made to minimize suffering.
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4.3. Coupling of Mouse Red Blood Cells with Hapten or Protein Antigen
Syngeneic MRBCs isolated from peripheral blood collected on anticoagulant (ethylenediaminetetraacetic
acid, EDTA) were chemically coupled with TNP hapten by 20 min incubation on roller, at room temperature,
and in darkness with 2,4,6-trinitrobenzene sulfonic acid (TNBSA, Eastman Chemicals, Rochester,
New York, NY, USA) dissolved in cacodylic buffer in a ratio of 40 mg of TNBSA per 7 mL of solution
per 1 mL of 100% MRBCs [14,16]. Afterwards, TNP-coupled MRBCs (TNP-MRBCs) were extensively
washed with DPBS. OX hapten (Sigma, St. Louis, MO, USA) for MRBC coupling was prepared
by dissolving in 96% ethanol in a ratio of 10 mg per mL (w/v) and rapid mixing with hot DPBS
on roller. Then, 10 mL of 10% DPBS suspension of MRBCs was mixed with 20 mL of OX solution
and incubated for 10 min on roller, at room temperature and in darkness [16]. Finally, OX-coupled
MRBCs (OX-MRBCs) were extensively washed with DPBS. MRBCs were coupled with BSA by 60-min
incubation on roller, at room temperature, of 1 mL of 50% MRBCs suspension in DPBS with 2.5 mL of 1%
BSA solution in DPBS in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Pierce,
Thermo Fisher Scientific, Waltham, MA, USA), used as coupling facilitating agents. At the end,
BSA-coupled MRBCs (BSA-MRBCs) were washed with DPBS.
4.4. Induction of Tolerance by Intravenous Administration of Antigen-Coupled Syngeneic MRBCs Prior to
Elicitation of CHS Reaction
Mice were intravenously injected on day 0 and 4 with 0.25 mL of nylon-filtered, 10% DPBS
suspension of either TNP-MRBCs, OX-MRBCs, or BSA-MRBCs. After next 3 days mice were
actively contact sensitized with either picryl chloride (PCL, trinitrophenyl chloride, Chemtronix,
Swannanoa, NC, USA) or OX by application of 0.15 mL of 5% PCL or 3% OX solution, respectively,
in an ethanol:acetone mixture (3:1 v/v) on shaved abdominal skin. Five days later mice were
challenged to elicit CHS by topical application of 10 µL of, respectively, 0.4% PCL or 0.4% OX in
acetone:olive oil mixture (1:1 v/v) on each side of both ears. After 24 h ear swelling was measured
with an engineer’s micrometer (Mitutoyo, Takatsu-ku, Kawasaki, Kanagawa, Japan) by a blinded
observer [16–18,42]. Background ear thickness, measured before challenge, was subtracted to yield
a value of ear thickness increase for each mouse. Nonspecific increase in ear thickness in nonsensitized,
but similarly challenged littermate animals, resulting from chemical skin irritation by hapten and
its vehicle, was subtracted from experimental groups to yield a net swelling value expressed as
delta ± standard error (SE) [U × 10−2 mm].
4.5. Isolation of Suppressive Exosomes Generated by Suppressor T Cells of Tolerized Mice and Adoptive Transfer
of CHS Effector Cells
Mice were injected twice with TNP or OX-coupled MRBCs and 3 days later epicutaneously
sensitized with PCL or OX solutions, as described above. Two days later lymph nodes and spleens
were collected for culture of their single cell suspensions (2 × 107 cells per mL) in protein-free
Mishell–Dutton medium [16–18] lasting for 48 h at 37 ◦C and 5% CO2. The resulting culture supernatant
was subsequently centrifuged at 300× g and 3000× g to remove cells and debris, filtered through
0.45 µm and 0.22 µm molecular filters and then ultracentrifuged twice at 100,000× g for 70 min at 4 ◦C.
Pelleted exosomes from tolerized mice were resuspended in DPBS [16] and used for 30-min incubation
in 37 ◦C water-bath with lymph node and spleen CHS effector cells collected from mice sensitized
with PCL or OX (see above) [16–18]. After washing, CHS effector cells were transferred intravenously
(7 × 107 cells per mouse) into naive recipients that were immediately challenged with PCL or OX to
elicit CHS response, as described above. The exact molecular characteristics of exosomes, confirmed
within the current study (Figure S1), along with confirmation of their Ts cell origin, was recently
reported [16,17]. Where indicated, exosomes were incubated overnight on ice with anti-hapten (TNP or
OX) monoclonal antibody kappa LCs [16], or heavy chains, both produced as formerly described [43],
followed by ultracentrifugation to remove unbound LCs or heavy chains. Control, nonsuppressive
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nanovesicles were obtained from ultracentrifuged supernatants of 48-h cultures of lymph node and
spleen cells from naive mice [16,18].
4.6. Data Analysis
Each experiment was carried out 2–3 times and the results of representative experiments were
shown in the figures. All groups consisted of five mice. Statistical significance of the data was estimated
(after control of meeting of test assumptions) in one-way Analysis of Variance (ANOVA) with post hoc
RIR Tukey test and p < 0.05 was considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/9/2656/s1.
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Abbreviations
BSA Bovine serum albumin
BSA-MRBCs Bovine serum albumin-coupled mouse red blood cells
CHS Contact hypersensitivity
LCs Light chains
MRBCs Mouse red blood cells
OX Oxazolone
OX-MRBCs Oxazolone-coupled mouse red blood cells
PCL Picryl chloride (trinitrophenol chloride)
TNBSA 2,4,6-trinitrobenzene sulfonic acid
TNP 2,4,6-trinitrophenol
TNP-MRBCs trinitrophenol-coupled mouse red blood cells
Ts T suppressor (cells)
WT Wild type
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